PROCESS NOW CLOSED.
Immediate Call for Applications
The Vall d´Hebron Institute of Oncology´s (VHIO) newly established Prostate Cancer Translational Research Group, led by Joaquin Mateo, is currently seeking to appoint a Post-doctoral Researcher. The successful candidate will form an integral part of the scientific team and will support the execution of the translational research program of the group, focused in drug development and study of correlative biomarkers in advanced prostate cancer.
This new group will include 4-5 biomedical scientists by Q3-4 2018 and will work in close collaboration with the GU Tumors Group of medical oncologists at VHIO towards the planning and development of precision medicine clinical trials in prostate cancer.
The main objective of the successful candidate will be to lead a research plan focused on biomarker refinement and drug sensitivity studies for DNA repair defects in prostate cancer.
He/she will develop in-vitro drug sensitivity studies using different prostate cancer cell lines to study the impact of AR, TP53 and PTEN signaling in DNA repair function in the presence of DNA repair gene alterations. The appointed individual will also work on the optimization of functional assays in patients´ cancer biopsies and the correlation between these assays and genomics, with the ultimate aim of developing tests for patient stratification in the clinic.
This investigator will be also be key in setting up and developing a precision medicine core for prostate cancer patients at VHIO, working together with the GU cancers medical oncology group and VHIO´s Cancer Genomics Group in the development of clinical trials at our Institute with correlative biomarker work performed at the laboratory.
An organized, motivated and team-oriented individual with previous experience in a translational research laboratory, ideally with previous experience in cancer research.
We are looking for someone with leadership skills with the ability to plan, develop and execute research projects coupled with a translational, patient-centered vision of biomedical research. While there is already an established research plan, we are seeking someone with initiative who will ultimately be responsible for developing our research strategy according to emergence of data and personal research interests. The candidate is expected to have had prior experience as postdoctoral researcher.
Prior involvement in work with clinical trial samples will be highly valued. The candidate is expected to be able to communicate in English, even if it is not his/her first language. The candidate will progressively be involved in grant proposals and the writing of manuscripts.
The ideal candidate should be familiar with:
- Working with human tissue and human genomic material.
- Regulatory requirements specifically for laboratories working in clinical trials.
- DNA and RNA extraction and processing. Background in clinical genomics and next-generation sequencing assays will be favorably considered.
- Cell line work and knock-out/knock-in experiments using siRNA, shRNA and, ideally (albeit not mandatory) with prior experience in gene editing using CRISPR technologies.
- Protein-based assays (Western blot, IF)
- Prior experience in preparing applications for grant funding and manuscript preparation will be valued.
Potential candidates should submit a curriculum vitae, letter of intent, and at least one reference via email addressed to Joaquin Mateo: email@example.com
Review of applications will commence immediately; interviews will be arranged with short-listed candidates.
The candidate should be available to join the group ideally by January 2018, although there is some flexibility according to the circumstances of the candidate, to be discussed during interviews.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), created by José Baselga in 2007, has established itself as a comprehensive cancer centre of proven excellence internationally. It is thanks to Josep Tabernero´s directorship and VHIO´s optimal organisational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO´s pioneering model and programmes, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumour types.